TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05472376

Intervention type: OTHER
Intervention: Retrospective study
Description: Retrospective study

Intervention type: OTHER
Intervention: Retrospective study
Description: Retrospective study

Intervention type: OTHER
Intervention: Retrospective study
Description: Retrospective study

Intervention type: OTHER
Intervention: Retrospective study
Description: Retrospective study

Intervention type: OTHER
Intervention: Retrospective study
Description: Retrospective study
Study: NCT05032287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Tamsulosin 0.4 mg once daily
Study: NCT03566147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human primary Retinal Pigment Epithelial (HuRPE) cells
Description: HuRPE will be transplanted by a board-certified vitreoretinal surgeon, which will be administered into the subretinal space of experimental eye through a standard surgical approach.
Study: NCT05032287

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study: NCT03042195

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral Nutrition
Description: Supplementary parenteral nutrition to achieve 100% coverage of estimated needs
Study: NCT00440141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005% eye drops and brimonidine 0.1% eye drops
Description: latanoprost 0.005%, 1 drop nightly for 3 months and brimonidine 0.1% three-times daily for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops
Description: latanoprost 0.005% 1 drop nightly for 3 months AND brinzolamide 1.0% 1% three-times daily for 3 months
Study: NCT02941198

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GyneFix
Description: The fiber is fixed to the anchoring thread by means of a stainless steel clip 1 cm from the upper part of the anchoring knot. The anchoring knot is implanted into the myometrium of the uterus thus permanently securing the implant in the uterine cavity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cu T380 A
Description: Cu T380 A will be inserted into the uterus
Study: NCT01846416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Description: Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Description: Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Description: Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle until disease progression.
Study: NCT00637338

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04603629
Description: Subjects will be given either PF-04603629 or Placebo in a blinded fashion. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given either PF-04603629 or Placebo in a blinded fashion during the study. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
Study: NCT02634671

Intervention type: OTHER
Group type: OTHER
Intervention: schizophrenia
Description: The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia with a control group using an experimental paradigm based on electroencephalography (EEG)

Intervention type: OTHER
Group type: OTHER
Intervention: the 22q11 deletion syndrome
Description: The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the schizophrenia and 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the schizophrenia and 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
Study: NCT03942172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpotOn balance glasses
Description: SpotOn Balance Glasses comprising of personalized visual stimuli placed on the glasses's lenses
Study: NCT00938093

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: Participants receive 10 telephone therapy sessions and an accompanying workbook focused on cognitive-behavioral techniques for managing anxiety.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced usual care
Description: Participants receive written information about anxiety, referrals for treatment, and an optional letter to their primary care physician.
Study: NCT02076243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel (abraxane) administered weekly (days 1,8, and 15 of 28 day cycle) to patients with unresectable locoregional or distantly metastatic cutaneous squamous cell carcinoma (SCC).
Study: NCT04594304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Usual care plus eToolkit
Description: A baseline e-survey will be sent to participants prior to their scheduled appointment to collect baseline alcohol/tobacco use levels as well as a series of questions evaluating precursors to behaviour change. If randomized into the intervention group, patients will be sent a link to a tailored toolkit based on their behaviours, motivation to change and other pertinent factors. Patients who identify as non-smokers and meet the low-risk drinking guideline, will complete a third screening survey for physical activity. The cumulative patient profile (CPP) status for the patient for alcohol/smoking will be automatically updated post-baseline survey, and the PCP will receive a notification via EMR about the status update. For patients identifying with risky behaviours, the PCP will receive a prompt to update the CPP for the patient and will receive a link, embedded in the EMR, to a PCP-facing toolkit that facilitates evidence-based intervention.
Study: NCT00787852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47
Description: Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib \& Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43~Dasatinib is to be taken 1x daily~1. 50 mg daily 100 mg daily~2. 70 mg daily 100 mg daily~3. 100 mg daily 100 mg daily~Maintenance x 2 years\*

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38
Description: Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib \& Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36~Dasatinib is to be taken 1x daily~1. 50 mg daily 100 mg daily~2. 70 mg daily 100 mg daily~3. 100 mg daily 100 mg daily Maintenance x 2 years\*
Study: NCT02714582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedside shift report
Description: Bedside shift report is a process where shift-to-shift report between nurses is, if approved by the patient, executed at the patient's bedside in order to improve the patient's involvement (Anderson \& Mangino 2006).
Study: NCT03395860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: group A:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-3-d-2 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3 group B:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-2-d-1 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: group A:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-3-d-2 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3 group B:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-2-d-1 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
Study: NCT02924272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib Capsules
Study: NCT00576368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: The physician will be guided by the prescribing information outlined in the summary of product characteristics. The administration will be done by once daily subcutaneous injection.
Study: NCT03140657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanocurcumin
Description: Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 months
Study: NCT02549521

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral magnesium substitution
Description: The elderly was given tablets two times daily with calsium and vitamin D. They were further given magnesium tablets 120 mg two times daily for 28 days.
Study: NCT00023504

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax
Description: To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabavert
Description: To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
Study: NCT02549521

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets without magnesium
Description: The elderly was given tablets two times daily with calsium and vitamin D. They were further given placebo without magnesium two times daily for 28 days.
Study: NCT00256646

Intervention type: DRUG
Intervention: Rosiglitazone
Description: ROSIGLITAZONE (roe si GLI ta zone) helps to treat type 2 diabetes. It helps to control blood sugar. Treatment is combined with diet and exercise.
Study: NCT04548479

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEP bottle
Description: PEP bottle: it will be performed with a bottle of distilled water and a plastic tube, where the patient breathes against a resistance during expiration.
Study: NCT02822352

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chromoendoscopy
Description: High definition virtual chromoendoscopy
Study: NCT03334656

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological dressing
Description: to test a biological dressing on the wound healing of the split-thickness skin graft donor site
Study: NCT00753493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous topiramate
Description: Single 25 mg IV dose given in addition to subject's normal morning dose of topiramate
Study: NCT05565508

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new laparoscopic access technique for group a
Description: new laparoscopic access technique through the epigastric region
Study: NCT03334656

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paraffin gauze dressing
Description: standard intervention : Paraffin gauze dressing on the wound healing
Study: NCT02460172

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zip Surgical Skin Closure
Description: Non invasive, reversible, skin closure device for closure of the skin layer following surgical incisions or laceration repair.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Steel Staples
Description: Skin closure device for the closure of the skin layer following surgical incision
Study: NCT04485936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epitomee Device
Description: medical Device designed to enhance the feeling of early satiation and prolonged satiety
Study: NCT03616249

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep
Description: Initially, all volunteers will undergo the following pre and post-intervention tests: Polysomnography; Actigraphy for 10 days; Maximum exercise test; blood collection; Physical performance evaluation; Assessment of muscle strength, assessment of body composition; And application of questionnaires.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep
Description: Initially, all volunteers will undergo the following pre and post-intervention tests: Polysomnography; Actigraphy for 10 days; Maximum exercise test; blood collection; Physical performance evaluation; Assessment of muscle strength, assessment of body composition; And application of questionnaires.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep
Description: Initially, all volunteers will undergo the following pre and post-intervention tests: Polysomnography; Actigraphy for 10 days; Maximum exercise test; blood collection; Physical performance evaluation; Assessment of muscle strength, assessment of body composition; And application of questionnaires.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep
Description: Initially, all volunteers will undergo the following pre and post-intervention tests: Polysomnography; Actigraphy for 10 days; Maximum exercise test; blood collection; Physical performance evaluation; Assessment of muscle strength, assessment of body composition; And application of questionnaires.
Study: NCT00023504

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar
Description: To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
Study: NCT03616249

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: After these procedures, the sarcophagic elderly will Resistance training, will be performed according to the latest positioning of the American College of Sports Medicine for the training of the elderly . The training will last 12 weeks, 3 times / week, with intervals of 48h between the training sessions, which will have a maximum duration of 60min. The periodization of the training will be done in a linear way, in which the volunteers will be submitted to training with 1 series of 12 to 15 repetitions at 60% of 1RM in the first week; In the second week volunteers will train at 70% of 1RM, performing 2 sets of 10 to 12 repetitions; And from the third week to the end of the training period the volunteers will train at 80% of 1RM performing 3 sets of at most 8 replicates and the intervals between sets may range from 60min to 180min. The training load will be readjusted in the 6th week of training from a new 1RM test and the training will be on the same test equipment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: After these procedures, the sarcophagic elderly will Resistance training, will be performed according to the latest positioning of the American College of Sports Medicine for the training of the elderly . The training will last 12 weeks, 3 times / week, with intervals of 48h between the training sessions, which will have a maximum duration of 60min. The periodization of the training will be done in a linear way, in which the volunteers will be submitted to training with 1 series of 12 to 15 repetitions at 60% of 1RM in the first week; In the second week volunteers will train at 70% of 1RM, performing 2 sets of 10 to 12 repetitions; And from the third week to the end of the training period the volunteers will train at 80% of 1RM performing 3 sets of at most 8 replicates and the intervals between sets may range from 60min to 180min. The training load will be readjusted in the 6th week of training from a new 1RM test and the training will be on the same test equipment.
Study: NCT03887052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASSURE™ Wearable Cardioverter Defibrillator (WCD)
Description: WCD with shock alarms and shock functionality disabled
Study: NCT00597532

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy
Description: soy (soy protein supplementation 50 grams/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk
Description: placebo (milk protein supplementation 50 grams/day)
Study: NCT04803890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No-Touch Radiofrequency Ablation
Description: No-Touch Radiofrequency Ablation Using Octopus Electrodes and Combined RF Energy Delivery Mode
Study: NCT04189380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HLQ (Health literacy questionnaire)
Description: each patient complete survey and self-assessment questionnaire before or after his medical consultation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MoCA (Montreal Cognitive Assessment)
Description: each patient complete survey and self-assessment questionnaire before or after his medical consultation
Study: NCT02545972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus extended release
Description: daily dosing of tacrolimus
Study: NCT00023504

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus diphtheria toxoid
Description: To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
Study: NCT03791489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClariFix
Description: The ClariFix™ device (K162608) is an FDA 510(k) cleared Class II cryosurgical tool indicated for the destruction of unwanted tissue during surgical procedures, including in adults with chronic rhinitis.
Study: NCT02503735

Intervention type: DRUG
Group type: OTHER
Intervention: Sofosbuvir/Ledipasvir FDC
Description: 12 weeks treatment with Harvoni
Study: NCT01740947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)
Description: SDD suspension contains per dose of 10 ml 100 mg colistin sulfate, 80 mg tobramycin and 500 mg amphotericin B
Study: NCT04648553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-Based Grounding
Description: Three 50 minutes sessions with an interventionist that includes 6 non-punitive components of treatment common in Behavioral Parent Trainings: Education on behavior change, positive one-on-one time between parents and their children, differential attending to positive and negative behaviors, effective praise, giving effective instructions, and using a point and reward system to encourage prosocial behaviors. These components are distilled into 5 skill modules and paired with Task-Based Grounding, which involves a brief restriction of privileges and provides children with the opportunity to end the restriction by completing a prosocial task.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Connected Care (Enhanced Treatment as usual)
Description: Two sessions with a facilitator. The facilitator does NOT provide any guidance to the parent on managing their child's behavior, but provides empathy and problem solving to help them find a resource that best fits their needs. It is particularly geared towards helping parents connect with Behavioral Parent Trainings to address the needs of children with oppositional, defiant, or aggressive behaviors.
Study: NCT02160574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep
Description: The degree of skin irritation caused by ChloraPrep will be graded and compared to ZuraPrep and ZuraPrep without IPA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% Sodium Lauryl Sulfate
Description: The degree of skin irritation caused by 0.1% Sodium Lauryl Sulfate will be graded and compared to ZuraPrep and ZuraPrep without IPA.
Study: NCT01836367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol Mebutate 0.015%
Description: Picato
Study: NCT02160574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Physiological Saline
Description: The degree of skin irritation caused by 0.9% Physiological Saline will be graded and compared to ZuraPrep and ZuraPrep without IPA.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ZuraPrep without IPA
Description: Results from exposure to ZuraPrep will be compared statistically those from exposure to ZuraPrep without IPA
Study: NCT04546945

Intervention type: DIAGNOSTIC_TEST
Intervention: CD56
Description: detection of CD56 by flow cytometry

Intervention type: DIAGNOSTIC_TEST
Intervention: CD56
Description: detection of CD56 by flow cytometry
Study: NCT00580190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam
Description: tablet, 0.5 mg, single dose, only on Day 7 of the study

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution, matching placebo to 500 mg PF-00572778, single dose, Days 1 and 7 of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00572778
Description: solution, 500 mg, single dose, only on Day 7 of the study
Study: NCT00230607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agalsidase beta
Description: Pharmaceutical form: powder for reconstitution Route of administration: intravenous